Dynavax Technologies Corporation

Dynavax Technologies Corporation, a biopharmaceutical company registered in SAM.gov since April 28, 2022, specializes in vaccines and medical countermeasures with a focus on immune system responses for disease prevention and treatment. The company is headquartered in Emeryville, California and maintains an active federal contracting presence across multiple government agencies, including the Centers for Disease Control and Prevention, Department of Veterans Affairs, Department of Defense, and Department of Health and Human Services. Through its federal contract portfolio, Dynavax provides critical pharmaceutical products and services that support national public health priorities, military medical preparedness, and clinical research initiatives.

Dynavax's federal contract work demonstrates extensive expertise in vaccine procurement and delivery, with the company serving as a prime contractor for multiple indefinite delivery vehicles and supply schedule arrangements. The company has provided adult vaccines including hepatitis A and B, herpes zoster, human papillomavirus, meningococcal, pneumococcal, and varicella formulations through several CDC contracts spanning 2022 through 2026, with contract values ranging from approximately $28 million to $58 million annually. Beyond vaccine supply, Dynavax has supported specialized clinical research through an Other Transaction award from the Joint Program Executive Office for Chemical and Biological Defense focused on adaptive clinical trials for investigational plague vaccine research. The company also maintains a Federal Supply Schedule contract with the Department of Veterans Affairs, specifically the Veterans Integrated Service Network 12, valued at $102 million through September 2028, under which it provides drugs, pharmaceuticals, and hematology-related products to support veteran healthcare delivery. Additionally, Dynavax received a single delivery order from the Federal Correctional Institution Big Spring through a McKesson Controlled contract vehicle. None of Dynavax's federal contract awards have utilized set-aside designations, indicating the company has competed on a full and open basis across all procurements.

Dynavax currently holds multiple active Indefinite Delivery Vehicle contracts that establish frameworks for task order issuance across federal agencies. The company maintains a $58.455 million CDC contract for adult vaccines with a performance period through June 30, 2026, representing a renewal of its ongoing relationship with the Centers for Disease Control and Prevention's National Center for Immunization and Respiratory Diseases for supporting national immunization programs. Dynavax also holds a $43.842 million Other Transaction IDV awarded by the Joint Program Executive Office for Chemical and Biological Defense on December 20, 2024, focused on the development of medical countermeasures for protection against pneumonic plague, which provides enhanced flexibility for innovative approaches to medical countermeasure development. The company maintains a $102 million Federal Supply Schedule contract under the Pharmaceuticals and Drugs (FSS-61-IB) schedule with the Department of Veterans Affairs through September 2028, and previously held CDC adult vaccine contracts valued at $56.205 million and $56.203 million for the fiscal years 2022-2023 and 2023-2024 respectively. An additional Other Transaction IDV valued at $38.701 million, awarded by the Joint Program Executive Office for Chemical and Biological Defense in September 2021, supports adaptive clinical trials for biological response modifiers related to investigational vaccine development. These contract vehicles collectively position Dynavax as a significant federal supplier of vaccines, pharmaceuticals, and medical countermeasures across defense, health, and veteran-focused agencies.